IPROVE
Innovation Partnership for a Roadmap on Vaccines in Europe
| Coordinatore | FEDERATION EUROPEENNE D'ASSOCIATIONS ET D'INDUSTRIES PHARMACEUTIQUES
Organization address
address: RUE DU TRONE 108/1 contact info |
| Nazionalità Coordinatore | Belgium [BE] |
| Totale costo | 670˙419 € |
| EC contributo | 496˙367 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2013-INNOVATION-1 |
| Funding Scheme | CSA-SA |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-12-01 - 2016-03-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
FEDERATION EUROPEENNE D'ASSOCIATIONS ET D'INDUSTRIES PHARMACEUTIQUES
Organization address
address: RUE DU TRONE 108/1 contact info |
BE (BRUXELLES) | coordinator | 153˙440.00 |
| 2 |
SCLAVO VACCINES ASSOCIATION
Organization address
address: PIAZZA LA LIZZA 7 contact info |
IT (SIENA) | participant | 182˙500.00 |
| 3 |
EATRIS ERIC
Organization address
address: DE BOELELAAN 1118 contact info |
NL (AMSTERDAM) | participant | 82˙008.08 |
| 4 |
EUROPEAN VACCINE INITIATIVE - EEIG
Organization address
address: IM NEUERHEIMER FELD 307 contact info |
DE (Heidelberg) | participant | 78˙067.00 |
| 5 |
STICHTING EATRIS
Organization address
address: LAAN VAN NIEUW OOST INDIE 334 contact info |
NL (DEN HAAG) | participant | 351.92 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
Under the leadership of the major Europe-based vaccine industry players, IPROVE (Innovation Partnership for a Roadmap on Vaccines in Europe) will produce a comprehensive roadmap on the future of vaccine R&D, production and delivery in the EU. IPROVE aims to drive current EU research efforts towards the establishment of a clear vision of the priority innovations and technologies necessary to address infectious and non-infectious threats of importance not only to global public health, but also to today’s key EU health challenges (e.g. ageing population, healthcare-associated infections, high chronic disease incidence, low levels of prevention awareness, and suboptimal use of existing cost-effective vaccines across the lifespan). The roadmap will explore how the wealth of expertise available across academia, industry, SMEs, public health institutes, and regulatory bodies can be pooled and leveraged to overcome fragmentation and removal of bottlenecks to the timely translation of breakthrough research into innovative vaccines. The project will look at the entire innovation chain, from discovery to delivery, including interventions necessary to improve education curricula, perception and awareness. IPROVE proposes to achieve its goal using a consultation-based stakeholder collaborative process bringing together the key public and private players in the vaccine field in Europe and beyond. This will contribute to understanding the scientific, political and economic potential to be tapped in order to favour a more structured vaccine innovation agenda. The roadmap is expected to inform strategic decisions on the priorities for future vaccine investment at EU and MS level. The exercise is considered key to secure that the EU is capable of tackling changing medical needs and strained healthcare system budgets. Strengthening the EU’s vaccine research base will also protect and grow the EU’s economic competitiveness in this area, where Europe has traditionally maintained a position of leadership.